acid), on pancreatic cancer cell proliferation and survival. AGN193198 treatment reduces BxPC-3 cell proliferation more efficiently than high-affinity retinoid acid receptor (RAR)-or retinoid X receptor (RXR)-selective retinoids. Moreover, AGN193198 does not activate transcription from RAR or RXR response elements and its effects on cell survival are not reversed by treatment with RAR-or RXR receptorselective antagonists. These results suggest that the AGN193198-dependent inhibition of BxPC-3 cell function is not mediated via activation of the classical retinoid receptors. Cell cycle analysis of AGN193198-treated BxPC-3 cells indicates that AGN193198 causes accumulation of cells in G2/M. This change is associated with a marked reduction in regulators of S (cyclin A, cyclindependent kinase (cdk)2), G2/M (cyclin B1, cdk1, cdc25c) and G1 (cyclin D1, cyclin E, cdk2, cdk4) phase, and an increase in p21 and p27 level. Kinases assays reveal that cdk1, cdk2 and cdk4 activity are suppressed in AGN193198-treated cells. In addition, reduced cell proliferation is associated with enhanced procaspase (3, 8 and 9) and PARP cleavage. Z-VAD-FMK, a pancaspase inhibitor, inhibits AGN193198-dependent caspase activation and attenuates cell death. Z-VAD-FMK inhibits PARP cleavage, but does not alter the AGN193198-dependent reduction in cell cycle regulatory protein expression and activity, suggesting that caspase activation and suppression of cell cycle regulatory protein levels are independent processes. AGN193198 produces similar responses in other pancreatic cancer cell lines including AsPC-1 and MIA PaCa-2. These studies suggest that AGN193198 may be useful for the treatment of pancreatic cancer.
Retinoid-related molecules are important potential agents for the treatment of cancer. In the present study, we test the effect of a novel retinoid-related ligand, AGN193198 (4-[3-(1-heptyl-4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3-oxo-prophenyl] benzoic acid), on pancreatic cancer cell proliferation and survival. AGN193198 treatment reduces BxPC-3 cell proliferation more efficiently than high-affinity retinoid acid receptor (RAR)-or retinoid X receptor (RXR)-selective retinoids. Moreover, AGN193198 does not activate transcription from RAR or RXR response elements and its effects on cell survival are not reversed by treatment with RAR-or RXR receptorselective antagonists. These results suggest that the AGN193198-dependent inhibition of BxPC-3 cell function is not mediated via activation of the classical retinoid receptors. Cell cycle analysis of AGN193198-treated BxPC-3 cells indicates that AGN193198 causes accumulation of cells in G2/M. This change is associated with a marked reduction in regulators of S (cyclin A, cyclindependent kinase (cdk)2), G2/M (cyclin B1, cdk1, cdc25c) and G1 (cyclin D1, cyclin E, cdk2, cdk4) phase, and an increase in p21 and p27 level. Kinases assays reveal that cdk1, cdk2 and cdk4 activity are suppressed in AGN193198-treated cells. In addition, reduced cell proliferation is associated with enhanced procaspase (3, 8 and 9) and PARP cleavage. Z-VAD-FMK, a pancaspase inhibitor, inhibits AGN193198-dependent caspase activation and attenuates cell death. Z-VAD-FMK inhibits PARP cleavage, but does not alter the AGN193198-dependent reduction in cell cycle regulatory protein expression and activity, suggesting that caspase activation and suppression of cell cycle regulatory protein levels are independent processes. AGN193198 produces similar responses in other pancreatic cancer cell lines including AsPC-1 and MIA PaCa-2. These studies suggest that AGN193198 may be useful for the treatment of pancreatic cancer.
Introduction
Pancreatic adenocarcinoma is the fourth leading cause of cancer death in the United States (Arbuck, 1990) . Fatality rates are extremely high, and advances in treatment have not improved survival rates (Arbuck, 1990; Rosenberg, 2000) . The median survival time of pancreatic cancer patients is 4-6 months and the overall 5-year survival rate is less than 2% (Rosenberg, 2000) . Nearly 100% of pancreatic cancer patients develop metastases and die. Risk factors include cigarette smoking, family history and the presence of certain genetic diseases ; protective factors include a diet rich in fruits and vegetables (Ji et al., 1995) . Pancreatic cancer genesis involves early mutations in Her-2/neu and K-ras, and subsequent mutations in p16 and p53, DPC4 and BRCA2 (Hruban et al., 2000) . Owing to of the severity of this disease and the poor prognosis, new approaches for prevention and treatment are necessary.
Retinoids are important potential cancer therapy and prevention agents (Altucci and Gronemeyer, 2001; Fontana and Rishi, 2002; Hammond et al., 2002; Ortiz et al., 2002; Sun and Lotan, 2002) . Retinoids are a class of natural and synthetic vitamin A analogs that regulate a range of biological processes including cell growth, cell differentiation and apoptosis (Petkovich et al., 1987; Brand et al., 1988) . The biological activity of retinoids are mediated by two families of nuclear ligandactivated receptors, the retinoic acid receptors (RAR), and the retinoid X receptors (RXR), which are members of the steroid hormone receptor gene super family (Zelent et al., 1989; Heyman et al., 1992; Mangelsdorf et al., 1992) . The RAR and RXR receptor subgroups each include a, b and g isoforms. RARa, b and g bind to all-trans retinoic acid, while RXRa, b and g interact with 9-cis-retinoic acid (Zelent et al., 1989; Heyman et al., 1992; Mangelsdorf et al., 1992; Rosewicz et al., 1995; Kawa et al., 1997; Pettersson et al., 2001 Pettersson et al., , 2002 .
Recent studies identify a new class of retinoid-related molecules (RRMs). Several different types of these compounds have been described including heteroarotinoids. Some heteroarotinoids have been reported to suppress cell survival via retinoid receptor-independent mechanisms, while others appear to require receptor function (Spruce et al., 1991; Benbrook et al., 1998; Chun et al., 2003; Liu et al., 2004) . Several RRMs, including N-(4-hydroxyphenyl) retinamide (fenretinide) and 6-[3-(-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437), ST1926, MM002, MM11453 and MX-3350-1, have been studied in several systems (Dawson et al., 2001; Garattini et al., 2004a, b; Zuco et al., 2004) . These agents promote apoptosis in a variety of tumor cell types and frequently display reduced toxicity compared to classical retinoids. Fenretinide induces apoptosis of prostate and ovarian cells and prevents oral leukoplakia (Chiesa et al., 1992; Pienta et al., 1993; Supino et al., 1996; Hsieh and Wu, 1997; Ortiz et al., 2002) . CD437 induces receptor-independent apoptosis in lung, cervical, breast and ovarian cancer cells (Shao et al., 1995; Hsu et al., 1997; Oridate et al., 1997; Sun et al., 1997; Holmes et al., 2003) . Some RRMs induce cancer cell apoptosis by retinoid receptorindependent mechanisms that frequently involve altered mitochondrial function (Dawson et al., 2001; Ortiz et al., 2002) . These findings confirm that potential importance of RRMs as candidate therapeutic agents.
AGN193198, 4-[3-(1-heptyl-4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3-oxo-prophenyl] benzoic acid, is a new RRM (Keedwell et al., 2004) . This molecule does not interact efficiently with or transactivate retinoid receptors, but it efficiently inhibits the growth of prostate cancer cells by a mechanism that involves rapid mitochondrial lysis and induction of caspase-dependent apoptosis (Keedwell et al., 2004) . In the present study, we show that AGN193198 inhibits pancreatic cancer cell proliferation via a unique mechanism -it promotes a global reduction in G1, G2/M and S phase cyclin and cyclin-dependent kinase (cdk) regulatory protein expression and activity, leading to growth arrest in the G2/M phase of the cell cycle. In addition, it promotes caspase-associated apoptosis. These actions appear to be retinoid receptor independent.
Results

AGN193198 inhibits pancreatic cancer cell proliferation more efficiently than RXR-or RAR-selective retinoids
We began by examining the effect of AGN193198 on pancreatic cancer cell proliferation. As shown in Figure 1a , treatment for 4 days with AGN193198 markedly suppresses BxPC-3 cell number. AGN193198, at 2 mM, is sufficient to maintain cell number at the initial level, while concentrations greater than 2 mM suppress cell number below this level. We next compared the ability of AGN193198 to suppress cell number relative to known receptor-selective retinoid agonists. Each retinoid was applied at receptor-saturating concentrations (K d values in Table 1 ). TTNPB is an RAR-selective retinoid and AGN194204 is an RXRselective retinoid (Strickland et al., 1983; Standeven et al., 2001) . As shown in Figure 1b , AGN193198 more efficiently suppresses cell number than TTNPB or AGN194204. This is surprising, since TTNPB and AGN194204 interact strongly with RAR and RXR receptors, respectively, while AGN193198 has a low affinity for these receptors. This suggests that AGN193198 may be functioning via a retinoid receptor-independent mechanism.
AGN193198 alters cell cycle progression and cell cycle regulatory protein expression
To determine whether the AGN193198-dependent reduction in cell number is associated with cell cycle perturbation, the distribution of cells in different phases of the cell cycle was measured at 24 and 48 h of AGN193198 treatment. As shown in Figure 2a , control cells are 81% diploid and 19% tetraploid. AGN193198 treatment results in a redistribution of diploid cells to the sub-G 1 and tetraploid states at 24 and 48 h. These findings suggest that cells growing in AGN193198 accumulate in the G2/M phase of the cell cycle. In addition, the sub-G 1 cell population increases from 1% in control cells to 11 and 20%, respectively, at 24 and 48 h of AGN193198 treatment.
Specific cyclins and cdk's interact in a cell cyclespecific manner to catalyse movement through the cell cycle. Thus, perturbation of cyclin or cdk expression may contribute to the altered cell cycle distribution. Cyclin D1 and cyclin E are expressed during the G1 phase, and cyclin D1-cdk4/6 and cyclin E-cdk2 complexes are required for G1 progression (Vermeulen et al., 2003) . Cyclin A is an S phase regulator, and cyclin B1, cdk1 and cdc25c are G2/M phase regulators. We therefore determined whether the suppression of cell proliferation and the accumulation of G2/M and sub-G 1 DNA content are linked to alterations in cell cycle regulatory protein expression. Total protein lysates were analysed by immunoblot. As shown in Figure 2b , the level of G1 regulators, including cyclin D1, cyclin E, and cdk2 and cdk4, are suppressed by AGN193198 treatment. In contrast, cdk6 levels are slightly suppressed. G2/M and S phase specific cell cycle regulatory markers are also suppressed -AGN193198 treatment suppresses cyclin A, cyclin B1, cdk1 and cdc25c level (Figure 2c ). Based on these findings, we anticipated that cdk activity should be reduced. Indeed, as shown in Figure 2d , direct assay confirms a reduction in cdk1, cdk2 and cdk4 activity; cdk6 activity is not regulated.
Cdk inhibitory proteins also regulate the cell cycle. These proteins, including p21 and p27, form a complex with cyclins and cdks and inhibit cdk activity and slow the cell cycle (McGowan, 2003) . Thus, AGN193198 may act to increase the level of these proteins. Figure 2e shows that p21 and p27 levels are increased in AGN193198-treated cells. Taken together, these findings suggest that AGN193198-dependent cell cycle arrest is associated with reduced activity of G1, S and G2/M phase-associated cdk's and increased levels of cdk inhibitor proteins (p21 and p27).
AGN193198 activates procaspase cleavage
We next investigated the possibility that AGN193198 may regulate apoptosis. Increased caspase activity is a hallmark of classical apoptosis (Shi, 2002) . The left panel in Figure 3a shows that AGN193198 treatment promotes cleavage of procaspase-3, procaspase-8 and procaspase-9. The right panel shows that this cleavage produces the expected products (asterisks). Poly(ADPribose) polymerase (PARP), an early marker of apoptosis (Nicoletti and Stella, 2003) , is also cleaved. The Bcl-2/Bax ratio is also known to influence cell death and survival. However, as shown in Figure 3b , the level of these regulators of apoptosis is not changed by AGN193198 treatment. These findings implicate caspase-dependent apoptotic processes in AGN193198-induced cell death. If caspases play an essential role, then a pancaspase inhibitor, Z-VAD-FMK, should partially reverse the AGN193198-dependent responses. As shown in Figure 4a , treatment of control cells with 20 mM Z-VAD-FMK does not alter cell number or alter PARP or procaspase-3 cleavage. However, Z-VAD-FMK treatment of AGN193198-treated cells partially reverses the AGN193198-dependent reduction in cell number (Figure 4a ), and nearly completely reverses the AGN193198-stimulated cleavage of procaspase-3 and PARP (Figure 4b ).
Apoptosis and cell cycle regulation
One possibility is that caspase activity may be required for the reduction in cell cycle regulatory protein level. To assess this, we examined the time course of AGN193198-dependent activation of caspase and the reduction in cell cycle regulatory protein level in BxPC-3 cells. As shown in Figure 5a , procaspase-8 cleavage is observed at 8 h and cleavage is optimal at 16-24 h after AGN193198 treatment. Cleavage of procaspase-3, procaspase-9 and PARP is observed at 16 and 24 h post-treatment; however, it is likely that cleavage occurs earlier. Figure 5b shows that cell cycle regulatory protein level is reduced at 16-24 h after the addition of AGN193198. These results suggest that caspase activity precedes and could be required for the reduction in cell cycle regulatory protein level. To test this possibility, cells were treated with AGN193198 in the presence or absence of Z-VAD FMK, a pancaspase inhibitor. As shown in Figure 5c , treatment with Z-VAD-FMK does not reverse the AGN193198-dependent reduction in The relative binding affinity of each retinoid was determined for the RAR and RXR subtypes using baculovirus-expressed RAR and RXRa, b and g as described previously Figure 2 Effect of AGN193198 on cell cycle. (a) Subconfluent BxPC-3 cells were treated with DMSO or 5 mM AGN193198 for 24 or 48 h, and then trypsinized and fixed in methanol. After washing with PBS, the cells were stained with propidium iodide and analysed by flow cytometry. Data shown are representative of three independent experiments. The number of events is represented on the y-axis and propidium iodide level (DNA content) on the x-axis. Peaks representing 2N (diploid) and 4N (tetraploid) DNA content, and subG1 DNA content are indicated. (b and c) Effect of AGN193198 on G1, S and G2/M phase cell cycle regulatory protein expression. Cells were treated with AGN193198 prior to the preparation of protein extracts, gel electrophoresis and immunoblot with antibodies specific for each indicated protein. b-actin levels were monitored to assure comparable protein loading. (d) AGN193198 treatment suppresses cdk activity. Using the methods outlined in the text, activity of cdk1, cdk2, cdk4 and cdk6 was monitored based on the ability to phosphorylate histone H1 (cdk1, cdk2) or Rb (cdk4, cdk6). (e) Effect of AGN193198 on cdk inhibitor level. Cells were treated with AGN193198 prior to the preparation of protein extracts for immunoblot with antibodies specific for p21 and p27. b-actin levels were monitored as a control for gel loading. These results are representative of three experiments cdk2, cyclin E, cyclin D1, cdk4, cdk1, and cyclin B1 level, suggesting that caspases do not play a major role in mediating this reduction. Based on these results, we would anticipate that Z-VAD-FMK treatment should inhibit the AGN193198-dependent accumulation of cells having sub-G1 DNA content, but not inhibit the AGN193198-dependent increase in cell number to the 4N state. Indeed, we observed that Z-VAD-FMK treatment inhibits the accumulation of cells having sub-G1 DNA content, but does not alter other changes in the cell cycle (i.e. the shift from 2N to 4N) (not shown).
AGN193198 responses are RAR and RXR independent
We next determined whether retinoid receptor activity is required for AGN193198 action. We first tested the ability of RAR-and RXR-selective antagonists to block the AGN193198-dependent reduction in cell number and increase in procaspase and PARP cleavage. BxPC-3 cells were treated with AGN193198 and increasing concentrations of AGN193109, a RAR-selective antagonist, or AGN195393, an RXR-selective antagonist. The cells were harvested and counted after 4 days of treatment. AGN193198 produces an 85% reduction in BxPC-3 cell number (Figure 6a and b). It is interesting that treatment with high receptor affinity RAR (Figure 6a ) or RXR ( Figure 6b ) antagonists does not reverse the AGN193198-dependent reduction in cell number. These antagonists saturate RAR isoforms (AGN193109) and RXR isoforms (AGN195393) at concentrations of 10-20 nM (Table 1) and, yet, do not inhibit the AGN193198-dependent reduction in cell number at concentrations up to 10 000 nM -ligand concentrations clearly sufficient to displace AGN193198 binding from the receptor. This finding suggests that the AGN193198-dependent decrease in cell number is receptor independent. In addition, these agents do not reverse the AGN193198-dependent increase in procaspase-3 and PARP cleavage (Figure 7a and b). Based on these findings, we reasoned that the AGN193198-dependent response may be retinoid receptor independent. To test this hypothesis, we measured the ability of AGN193198 to activate transcription in BxPC-3 cells. To assess the ability of AGN193198 to activate via an RAR mechanism, cells were cotransfected with the estrogen response element (ERE)-tk-Luc reporter plasmid and plasmids encoding estrogen receptor (ER)-RARa, ER-RARb or ERRARg. After 24 h, the cells were treated with the indicated retinoid for an additional 24 h. ER-RARa, Z-VAD-FMK treatment was initiated 30 min prior or to AGN193198 addition and continued thereafter. Extracts were then prepared, electrophoresed and immunoblotted with antibodies specific for the indicated G1 and G2/M cell cycle regulatory protein Figure 6 AGN193198-dependent suppression of cell number is RAR and RXR independent. BxPC-3 cells were plated at 6000/per cm 2 in 9.6 cm 2 dishes, and allowed to attach for 24 h. (a) Cells were treated with increasing concentrations of AGN193109 in the presence or absence of 3 mM AGN193198. Fresh medium and retinoid was added after 2 days, and the cells were harvested and counted after 4 days. (b) Cells were treated with increasing concentrations of AGN195393 in the presence or absence of 3 mM AGN193198. After 4 days, the cells were harvested and counted using a coulter counter. DMSO concentration was maintained constant in all treatment groups. Error bars (not shown) represent the mean7s.e.m. and were all within 15% of the mean but not by the RXR-selective retinoid, AGN194204, or by AGN193198. We next tested that ability of AGN193198 to activate expression via the RXRE (retinoid X response element) from the cellular retinoic acid binding protein II (CRBPII) gene. In RXRE-tkLuc, the RXRE is directly linked to tk-Luc. As shown in Figure 8b , only the RXR-selective ligand, AGN194204, activates this reporter construct. No effect is observed following treatment with TTNPB or AGN193198. Taken together, these findings suggest that AGN193198 regulates pancreatic cancer cell function via a nonretinoid receptor mechanism.
AGN193198 also inhibits the proliferation of other pancreatic cancer cell lines
The above findings show that AGN193198 inhibits BxPC-3 cell function. To assess whether AGN193198 also influences the function of other pancreatic cancer cell lines, we tested the effect of AGN193198 on AsPC-1 and MIA PaCa-2 cells. As shown in Figure 9a , AsPC-1 and MIA PaCa-2 cell number is reduced by AGN193198 treatment, but not as efficiently as the reduction observed for BxPC-3 cells. Figure 9b shows that, as was observed for BxPC-3 cells (Figure 1b) , AGN193198 reduces AsPC-1 and MIA PaCa-2 cell number more efficiently than a receptor-saturating level of RAR-or RXR-selective agonist.
Cell cycle analysis reveals that AGN193198 treatment of MIA PaCa-2 cells results in a marked increase in sub-G1 DNA content (Figure 10a ). In contrast, sub-G1 DNA content is only slightly increased in AsPC-1 cells. G2/M (4N) DNA content is increased in both cell lines, although the effect is not as prominent in the AsPC-1 cell line. Thus, as in BxPC-3 cells, AGN193198 treatment enhances the number of cells with G2/M DNA content. We also characterized procaspase and intact PARP level as biochemical markers of AGN193198 action. As shown in Figure 10b , minimal procaspase and PARP cleavage is observed in AGN193198-treated AsPC-1 cells. In contrast, AGN193198-treated MIA PaCa-2 cells display substantial cleavage of these apoptosis regulators.
Retinoid receptor level and retinoid regulation among pancreatic cancer cells
The previous experiment suggests that BxPC-3, MIA PaCa-2 and AsPC-1 cells have varied sensitivity to AGN193198. We hypothesized that this response should not be related to retinoid receptor content, as AGN193198 appears to act independently of these receptors. We therefore examined the retinoid receptor content of each cell line and the effects of AGN193198 on receptor expression. As shown in Figure 11 , all six receptor isotypes are expressed in MIA PaCa-2 cells. AsPC-1 cells express relatively higher levels of RARg, while BxPC-3 cells express RARb. All three cell types 2 ) were plated and permitted to attach for 24 h. Cells were seeded as described above and allowed to attach for 24 h before treatment with the indicated concentrations of TTNPB, AGN194204 or AGN193198. After 4 days of treatment, the cells were harvested and counted. The error bars represent the mean7s.e.m. for three separate experiments. The open bar indicates the cell numbers at time zero at the initiation of treatment AGN193918 regulates pancreatic cancer cell survival S Balasubramanian et al appear to express RXRa. However, some amount of each receptor is expressed in each of the cell types and AGN193198 treatment does not alter receptor levels. The only correlation with response to AGN193198 among the cell types is an inverse relationship between RARg level and the extent of biological response. The most responsive cell line, BxPC-3, has the lowest RARg content, while the least responsive cell line, AsPC-1, has the most. The moderately responsive cell line, MIA PaCa-2, has an intermediate level of RARg.
Discussion
Pancreatic cancer is the fifth leading cause of cancer death in the Western world (Arbuck, 1990) . Pancreatic tumors are highly resistant to the available therapies and the 5-year survival time is low with a median expected postdiagnosis survival time of five months (Arbuck, 1990; Rosenberg and Lipsett, 2003) . Owing to this poor prognosis, alternative therapies are being investigated. Vitamin A and other natural retinoids are important regulators of cell differentiation and development. As these agents control cell fate, apoptosis and differentiation, they are considered important candidates as anticancer therapeutics (Zusi et al., 2002; Paik et al., 2003; Vermeulen et al., 2003) . Thus, there is a major ongoing effort to develop retinoid analogs that possess a high therapeutic index, that is, an ability to inhibit tumor growth without adversely influencing surrounding tissues (Johnson and Chandraratna, 1999; Nagpal and Chandraratna, 2000; Hammond et al., 2002) . Preliminary clinical trials suggest that retinoids may be useful for the treatment or prevention of pancreatic cancer (Brembeck et al., 1998b) . Retinoids mediate their biological action by binding to nuclear, ligand-activated receptors (Petkovich et al., 1987; Brand et al., 1988) . Many pancreatic cancer cell lines express RARa and RXRg, although other RAR and RXR subtypes are also expressed (Albrechtsson et al., 2002) and previous studies show that natural retinoids can inhibit pancreatic cancer cell proliferation (Egawa et al., 1996; Rosewicz et al., 1996; Kawa et al., 1997; Brembeck et al., 1998a; Pettersson et al., 2001 Pettersson et al., , 2002 Albrechtsson et al., 2002) . Some reports suggest that the retinoidassociated inhibition of pancreatic cancer cell proliferation is RARa receptor dependent (Kaiser et al., 1998; Brembeck et al., 1998a; Pettersson et al., 2002) . For example, treating DSL-6A/C1 pancreatic adenocarcinoma cells with an RARa-selective synthetic retinoid suppresses cell proliferation, while treatment with an RARa-antagonist reverses this response (Brembeck et al., 1998a) . TAC-101, another RARa-selective synthetic retinoid, inhibits proliferation of BxPC-3, MIA PaCa-2 and AsPC-1 cells (Fujimoto et al., 1999) . RXRselective retinoids also inhibit pancreatic cancer cell function (Balasubramanian et al., 2004) . However, more efficacious agents are required, and so, in the present study, we examine the ability of a RRM to regulate pancreatic cancer cell function.
Retinoid-related molecules
Several RRMs, agents that effect cell function via retinoid receptor-independent mechanisms, have been described. For example, Shao et al. (1995) showed that CD437, causes growth arrest in G0/G1 with subsequent apoptosis in breast cancer cells via a retinoid receptorindependent mechanism. In these cells, apoptosis is associated with changes in Bax and Bcl-2 expression (Shao et al., 1995) . Sun et al. (1997) showed that CD437 inhibits non-small-cell lung carcinoma cell proliferation, and that the inhibition is not reversed by RAR-or RXR-selective antagonists. CD437 also inhibits bronchial epithelial cell function via a receptor-independent mechanism (Sun et al., 1999) . Hsu et al. (1997) showed that CD437 inhibits leukemia cell proliferation and increases apoptosis. These authors propose that this inhibition is via a retinoid receptor-independent mechanism, as these cells do not express the appropriate retinoid receptors. Fenretinide, a second RRM, induces apoptosis of prostate and ovarian cells and prevents oral leukoplakia (Chiesa et al., 1992; Pienta et al., 1993; Supino et al., 1996; Hsieh and Wu, 1997; Ortiz et al., 2002) . Only one RRM has been examined with respect to effects on pancreatic cancer cell function. Mofarotene (Ro 40-8757), a synthetic retinoid that does not bind to or activate retinoid receptor family members, suppresses pancreatic cancer cell proliferation (Crettaz et al., 1990; Teelmann et al., 1993) . Mafarotene inhibits pancreatic cancer cell proliferation by increasing p21 and p27, and causing arrest in G1 (Kawa et al., 1997) . In general, these studies show that RRMs causes cell cycle arrest in G0/G1 and/or induce apoptosis. Other RRMs have been described and, in general, they show enhanced efficacy with fewer side effects. They frequently kill cells via an apoptotic mechanism (Bayon et al., 2003; Garattini et al., 2004a, b; Lopez-Hernandez et al., 2004; Zuco et al., 2004) .
AGN193198 -an effective inhibitor of pancreatic cell proliferation
In the present experiments, we examined the ability of a new RRM, AGN193198, to regulate pancreatic cancer cell function. AGN193198 has previously been reported to reduce survival and proliferation of prostate cancer cells (Keedwell et al., 2004 ). The present study shows that AGN193198 is an effective inhibitor of pancreatic cancer cell proliferation. This is a potentially important finding, as achieving increased biological potency is an important clinical goal in treating pancreatic cancer. Typical of some other RRMs (Oridate et al., 1997; Sun et al., 1997; Lotan, 2003) , our results suggest that AGN193198 mediates its action via a receptorindependent mechanism. First, high-affinity RAR-and RXR-selective antagonists do not inhibit the effects of Figure 11 Retinoid receptor expression in BxPC-3, AsPC-1 and MIA PaCa-2 cells. Cell extracts were prepared from 50 to 70% confluent PaCa-2, AsPC-1 and BxPC-3 cells following treatment for 24 h with the indicated concentration of AGN193198. Equivalent quantities of protein were electrophoresed on a 10% acrylamide gel, transferred to nitrocellulose membrane and incubated with rabbit polyclonal antibodies specific for RARa, b and g and RXRa, b and g (Santa Cruz Biotechnology Inc., sc-551, sc-552, sc-550, sc-553, sc-531, sc-555). A parallel blot was incubated with anti-b-actin to assure equivalent protein loading AGN193198 on cell survival and caspase activity. Second, AGN193198, which has a low affinity for RAR-and RXR-receptors, is a more potent regulator of pancreatic cancer cell function than the high-affinity agonists, TTNPB (RAR selective) and AGN194204 (RXR selective) (Table 1) . Thus, the biological activity of AGN193198 is much greater than would be predicted from its poor receptor binding properties. Third, AGN193198 does not activate RAR-or RXR-dependent transcription. A unique feature of this regulation is the presence of global changes in cell cycle regulatory protein expression. Studies in BxPC-3, cells indicate that this agent markedly suppresses the level of multiple cell cycle regulatory proteins including G1 (cdk2, cdk4, cyclin D1 and cyclin E), G2/M (cyclin B1, cdc25c and cdk1) and S (cyclin A) phase regulators. Thus, changes are observed at all cell cycle stages. In addition, the level of the cdk inhibitors, p21 and p27, is increased. These findings suggest that the cells cease proliferation due to global changes in cdk, cyclin and cdk expression. Activity assays confirm that the decrease in cdk1, cdk2 and cdk4 level is associated with reduced total kinase activity. Time-course studies indicate that activation of caspases precedes the reduction in cell cycle regulatory protein level, suggesting that caspases may mediate the reduction in regulatory protein level. However, the fact that a pancaspase inhibitor does not attenuate the AGN193198-dependent reduction in cell cycle regulatory protein expression suggests that caspase activation is not necessary for the reduction in cell cycle protein expression.
A potentially important finding is the accumulation of cells in G2/M (4N DNA content). Increased G2/M DNA content has been previously described in pancreatic cancer models. For example, pancreatic tumors develop in transgenic mice expressing the SV40 Tantigen under the control of the elastase I promoter (Levine et al., 1991) . In these animals, the 4N state is associated with increased number of centrioles per cell. The authors speculate that the excess centrioles may predispose the cells to formation of multipolar mitosis, yielding daughter cells that have gained additional chromosomes. Such cells are thought to undergo subsequent apoptosis. In the present studies, we believe that the accumulation in G2/M must be a function of the relative level and activities of the kinases available during the initial stages of AGN193198 exposure. However, additional studies will be necessary to define the mechanism.
Role of apoptosis
In addition to increased G2/M phase cells, AGN193198-dependent pancreatic cancer cell death is associated with an increased number of cells containing sub-G1 DNA content. Indeed, there is a substantial increase in caspase (i.e. cleavage of procaspase-9, -8 and -3) and PARP cleavage in AGN193198-treated cells. This is perhaps not surprising, since, as outlined above, apoptosis is a hallmark of the mechanism of RRM action. Moreover, authentic retinoid receptor-interacting ligands, including all-trans retinoic acid, also induce caspase-associated apoptosis in pancreatic cancer cells (Fujimoto et al., 1999; Pettersson et al., 2000 Pettersson et al., , 2001 . Some studies also show that an altered Bcl-2/Bax ratio, in favor of Bax, is associated with RRM-dependent cell death (Pettersson et al., 2000) . However, the Bcl-2/Bax ratio was not observed to change in the present studies, suggesting that this change is not necessary for the effects of AGN193198.
As noted above, AGN193198 treatment results in growth arrest in G2/M, as well as, caspase-dependent apoptosis. An important issue is the relative contribution of growth suppression versus apoptosis to the reduction in cell number and survival. It is not presently clear which process is the major contributor to the reduction in cell number. It is also possible that both processes are required and that one process (i.e. accumulation of cells in G2/M) may lead to the other (caspase-dependent cell death). It is clear, however, that inhibition of caspase activity partially attenuates the AGN193198-dependent reduction in cell number, and that caspase activity is not required for the reduction in cell cycle regulatory protein level. We hypothesize that the increased cell survival in the presence of Z-VAD-FMK is strictly due to attenuation of caspase-dependent cell death, and that the reduction in cell cycle regulatory protein level is responsible for the remaining reduction in cell number. This hypothesis is supported by the observation that Z-VAD-FMK decreases the number of cells containing sub-G1 DNA content, but does not the alter in the percentage of cells displaying 4N DNA content.
Differential response of pancreatic cancer cell lines
Finally, it should be noted that the response to AGN193198 varies among the three cell lines tested. The growth suppression was the most dramatic in BxPC-3 cells, as was the shift to G2/M and subG1 DNA content, and the extent of the caspase activation. The MIA PaCa-2 cells were intermediate for growth suppression and for the other parameters. In contrast, the AsPC-1 cells were the least responsive for growth suppression. Moreover, there was no evidence for caspase activation in these cells and only a minimal accumulation of cells having sub-G1 DNA content. Accumulation of cells with G2/M DNA content was also reduced. However, the AsPC-1 findings do suggest that death may result from AGN193198 treatment in the absence of caspase activation. Thus, not every pancreatic cancer cell may undergo apoptosis. Moreover, these findings suggest, as is common with therapeutic agents, that the response can vary depending upon the properties of the particular tumor cell population that is being targeted. Finally, although there was no correlation between levels of RARa and b, and RXRa, b and g with response to AGN193198, we did observe an inverse correlation between the level of RARg and the responsiveness to AGN193198. The meaning of this relationship will require further study.
Materials and methods
Cell cultures
Human pancreatic cancer cell lines BxPC-3, AsPC-1 and MIA PaCa-2 cells were purchased from American Type Culture Collection (ATCC; Rockville, MD, USA). BxPC-3 cells were grown in RPMI supplemented with 2 mM L-glutamine 100 U/ ml penicillin, 100 U/ml streptomycin, 1 mM sodium pyruvate, 10 mM HEPES, 10% fetal bovine serum (FBS) and 4.5 g/l glucose. AsPC-1 cells were cultured in RPMI supplemented with 4 mM L-glutamine 100 U/ml penicillin, 100 U/ml streptomycin, 1 mM sodium pyruvate, 10 mM HEPES, 20% FBS and 4.5 g/l glucose. MIA PaCa-2 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 4 mM L-glutamine 100 U/ml penicillin, 100 U/ml streptomycin, 10% FBS and 2.5% horse serum.
Chemicals and reagents
AGN193198, AGN194204, TTNPB, AGN193109 and AGN195393 (Department of Chemistry, Allergan Inc.) were dissolved in dimethyl sulfoxide (DMSO) as 1000-fold concentration and stored in aliquots at À701C. Table 1 lists the binding affinity of each ligand for receptor. For cell culture experiments, the DMSO concentration in the medium did not exceed 0.2%. Z-VAD-FMK, a general caspase inhibitor, was obtained from BD PharMingen. Rabbit polyclonal antibodies specific for cdk2 (sc-163), cdk4 (sc-601), cdk6 (sc-7181), cyclin E (sc-481), procaspase-9 (sc-8355), Bax (sc-493), goat polyclonal antibody specific for procaspase-8 (sc-6136), and mouse monoclonal antibodies specific for p21/Waf1 (sc-6246), p27/ Kip1 (sc-1641) and Bcl-2 (sc-7382) were purchased from Santa Cruz Biotechnology. Rabbit polyclonal antiprocaspase-3 was purchased from Biosource (AHZ0052). Mouse monoclonal anti-b-actin was obtained from Sigma (A5441) and anti-cyclin D1 (554180) was from BD PharMingen. Mouse monoclonal antibodies specific for cdk1 (sc-54), cyclin A (sc-239), cyclin B1 (sc-245) and rabbit polyclonal antibody specific for Cdc25C (sc-237) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal anticaspase-9 (#9502) anticaspase-3 (#9665) and mouse monoclonal anticaspase-8 (#9746) were obtained from Cell Signaling.
[g-32 P]ATP was obtained from New England Nuclear Life Science Products. Histone H1 and Rb (amino acids 773-928) were received from Upstate Biotechnology. Anti-RARa, b and g and anti-RXRa, b and g were obtained from Santa Cruz Biotechnology (sc-551, sc-552, sc-550, sc553, sc-531, sc-555) . Mouse monoclonal anti-PARP was obtained from BD Pharmingen (55494).
Proliferation studies
Cells were seeded (AsPC-1 and BxPC-3 at 6000 cells/cm 2 ; MIA PaCa-2 at 2000 cells/cm 2 ) in complete medium and allowed to attach for 24 h. Cells were treated by the addition of fresh medium containing increasing retinoid concentrations. Treatment was continued for 4 days with the addition of fresh medium and retinoid every 2 days. After 4 days of treatment, the cells were harvested with 0.025% trypsin, 1 mM EDTA and counted using a coulter counter.
DNA cell cycle analysis
Subconfluent BxPC-3 cells were treated without or with AGN193198 for various time periods. The cells were trypsinized, washed twice with cold phosphate-buffered saline (PBS) and centrifuged. The pellets were resuspended in cold PBS, fixed in cold methanol and stored at À201C. For analysis, the cells were washed twice with cold PBS, suspended in PBS, incubated with RNAse (20 mg/ml final concentration) for 30 min, chilled over ice for 10 min, stained with propidium iodide (50 mg/ml final concentration) for 1 h and analysed by flow cytometry.
Cdk activity assay
BxPC-3 cells were lysed in a buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM sodium orthovanadate, 1 mg/ml leupeptin and 2 mM phenylmethylsulfonyl fluoride. Protein lysates (100-150 mg) were incubated with 2 mg of corresponding primary antibody for 2 h at 41C. Protein A/G plus agarose beads (25 ml) were then added and samples were rotated at 41C overnight. The beads were then washed three times with lysis buffer and once with kinase assay buffer (50 mM Tris (pH 7.5), 10 mM bglycerophosphate, 4 mM DTT, 20 mM MgCl 2 and 0.2 mM sodium orthovanadate). Cdk1 and cdk2 kinase activities were determined by incubating the beads in the 40 ml of kinase buffer containing (5 mg) of histone H1, 5 mCi of [g-32 P]ATP and 5 mM ATP for 30 min at 371C. Cdk4 and cdk6 kinase activities were measured by incubating the beads in the 40 ml of kinase buffer containing (2 mg) of Rb 773-928 (amino acids 773-928), 5 mCi of [g-32 P]ATP and 5 mM ATP for 30 min at 371C. The kinase reactions were stopped by the addition of 2 Â SDS sample buffer and boiled for 5 min. The samples were electrophoresed on 12% acrylamide gels and incorporation was visualized by autoradiography.
Cell lysate preparation and Immunoblot analysis
BxPC-3 cells were treated in the presence of 5 mM AGN193198 or 0.1% DMSO in the regular medium for 24 and 48 h. The cells were washed in PBS, and suspended in lysis buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM glycerophosphate, 1 mM sodium vanadate, 1 mg of leupeptin and 1 mM phenylmethylsulfonyl fluoride. Equal amounts of protein were electrophoresed on acrylamide gels (10%) and the separated proteins were transferred to nitrocellulose membrane. The membrane was incubated in 10 mM Tris-HCl (pH 7.2) containing 100 mM NaCl, 0.1% Tween-20 and 5% nonfat dry milk to block nonspecific binding. The membrane was then incubated with the primary antibody, washed, and incubated with corresponding horseradish peroxidase-conjugated secondary antibody. The membrane was washed and antibody binding was visualized by chemiluminescent detection methods.
Abbreviations RAR, retinoid acid receptors; RXR, retinoid X receptors; cdk, cyclin-dependent kinase; RRM, retinoid-related molecule; PARP, poly(ADP-ribose) polymerase.
